Rhinoconjunctivitis
53
4
4
46
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
1.9%
1 terminated out of 53 trials
97.9%
+11.4% vs benchmark
26%
14 trials in Phase 3/4
17%
8 of 46 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 46 completed trials
Clinical Trials (53)
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
Intervention in Chronic Pediatric Patients and Their Families.
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
Red Maple Trials Cat Allergen Natural Exposure Chamber Validation in Cat-allergic Subjects
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
Phase III Cat-PAD Study
Phase II HDM-SPIRE Safety and Efficacy Study